- Home
- / GSK
GSK Summary
Overview
GSK (GlaxoSmithKline) is a science-led healthcare company. It has three businesses that research, develop, and manufacture pharmaceutical medicines, vaccines, and consumer healthcare products. The company develops vaccines against infectious diseases and provides a portfolio of medicines in respiratory, HIV, immuno-inflammation, and oncology. GSK combines science and consumer insights aiming to create everyday healthcare brands for oral health, pain relief, cold, flu and allergy relief, digestive health, and vitamins, minerals, and supplements.
| Type | Public | |
| Founded | 2000 | |
| HQ | Brentford, GB | Map |
| Website | gsk.com | |
| Employee Ratings |   | More |
| Overall Culture | C+ | More |
Locations
Table of Contents
Key People/Management at GSK
GSK Office Locations
GSK has offices in Brentford, Philadelphia, Boudouaou, San Fernando and in 86 other locations
GSK Financials and Metrics
GSK Revenue
GSK's revenue was reported to be £33.75 b in FY, 2019 which is a 9.5% increase from the previous period.
GBP
| Revenue (Q3, 2020) | £8.65 b |
| Gross profit (Q3, 2020) | £5.76 b |
| Gross profit margin (Q3, 2020), % | 66.6% |
| Net income (Q3, 2020) | £1.43 b |
| EBIT (Q3, 2020) | £1.86 b |
| Market capitalization (11-Jun-2021) | £70.61 b |
| Closing stock price(11-Jun-2021) | £14.03 |
| Cash (30-Sept-2020) | £4.28 b |
| EV | $94.58 b |
GSK's current market capitalization is £70.6 b.
| GBP | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.4 b | 7.3 b | 7.8 b | 7.2 b | 7.3 b | 8.1 b | 7.7 b | 7.8 b | 9.4 b | 9.1 b | 7.6 b | 8.6 b |
| Cost of goods sold | 2.5 b | 2.6 b | 2.7 b | 2.4 b | 2.3 b | 2.6 b | 2.7 b | 2.6 b | 3.2 b | 3.2 b | 2.4 b | 2.9 b |
| Gross profit | 4.9 b | 4.7 b | 5.2 b | 4.8 b | 5 b | 5.5 b | 4.9 b | 5.2 b | 6.1 b | 5.9 b | 5.2 b | 5.8 b |
| Gross profit Margin, % | 66% | 64% | 66% | 67% | 68% | 67% | 64% | 66% | 65% | 65% | 68% | 67% |
| GBP | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | 4.5 b | 4 b | 4.7 b | 4 b | 4 b | 3.8 b | 4.1 b | 4.1 b | 4.3 b | 4.8 b | 8.2 b | 4.3 b |
| Inventories | 5.4 b | 5.7 b | 5.7 b | 5.7 b | 5.9 b | 5.8 b | 5.7 b | 6 b | 6.8 b | 6 b | 6.4 b | 6.4 b |
| Current Assets | 16.8 b | 16.4 b | 17.7 b | 16.4 b | 17 b | 17.4 b | 17.5 b | 18.2 b | 21 b | 22 b | 23 b | 19.9 b |
| PP&E | 10.8 b | 10.7 b | 10.6 b | 10.7 b | 10.8 b | 10.9 b | 10.3 b | 10.4 b | 10.7 b | 10.4 b | 10.5 b | 10.3 b |
| GBP | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Depreciation and Amortization | 326 m | 1.4 b | 2.1 b | 478 m | 673 m | 1.2 b | 1.2 b | 2 b | 2.5 b | 194 m | (971 m) | (330 m) |
| Cash From Operating Activities | 1.1 b | 2.2 b | 4 b | 863 m | 2.2 b | 4.3 b | 663 m | 2.1 b | 5.6 b | 965 m | 3.7 b | 4.6 b |
| Purchases of PP&E | (260 m) | (639 m) | (1 b) | (258 m) | (541 m) | (842 m) | (222 m) | (501 m) | (785 m) | (197 m) | (420 m) | (712 m) |
| Cash From Investing Activities | (199 m) | (646 m) | (1.1 b) | (371 m) | (633 m) | (1.1 b) | (4 b) | (4.5 b) | (5 b) | (58 m) | 2.8 b | 2.2 b |
GBP
Q3, 2020
| EV/EBIT | 52.1 x |
| EV/CFO | 21.1 x |
| Debt/Equity | 1.4 x |
| Debt/Assets | 0.3 x |
| Financial Leverage | 3.9 x |
| P/E Ratio | 58.8 x |
Revenue Breakdown
GSK revenue breakdown by business segment: 26.7% from Consumer Healthcare, 21.2% from Vaccines and 52.1% from Global Pharmaceuticals
GSK revenue breakdown by geographic segment: 23.9% from Europe, 34.9% from International and 41.2% from US
GSK Operating Metrics
GSK's Vaccine Doses Delivered per Day was reported to be 2 m in FY, 2019.
GSK Acquisitions / Subsidiaries
| Company Name | Date | Deal Size |
|---|---|---|
| Sitari Pharmaceuticals | September 12, 2019 | |
| TESARO | December 04, 2018 | $5.1 b |
| GlycoVaxyn | February 11, 2015 | $190 m |
| Okairos AG | May 29, 2013 | $325 m |
| Human Genome Sciences | August 03, 2012 | $3 b |
| CellZome | May 15, 2012 | £61 m |
| MaxiNutrition | December 13, 2010 | £162 m |
| Nanjing MeiRui Pharma Co., Ltd. | December 07, 2010 | $70 m |
| Laboratorios Phoenix | June 09, 2010 | $253 m |
| NovaMin Technology | May 24, 2010 | $135 m |
Human Capital Metrics
Source: www.gsk.com, www.gsk.com, www.gsk.com
GSK Hiring Categories
GSK Median Salaries
Source: 9 public H-1B filings from GSK
GSK Cybersecurity Score
GSK Environment, Social & Governance (ESG) Ratings
GSK Website Traffic
Alexa Website Rank
Total Visits per monthSimilarWeb
Twitter Engagement Stats for @gsk
12.45 k
Tweets
718
Following
223.55 k
Followers
105
Tweets last 30 days
14.3
Avg. likes per Tweet
85.7%
Tweets with engagement
GSK Technology Stack![BuildWith Logo]()
ads
7 products used
- DoubleClick.Net
- Facebook Custom Audiences
- Google Remarketing
- JW Player Tracking
- Rocket Fuel
- travel audience
- Twitter Ads
analytics
14 products used
- Adobe Marketing Cloud
- Clicktools
- Facebook Signal
- Global Site Tag
- Google Analytics
- Google Analytics Enhanced Link Attribution
- Google Conversion Tracking
- Google Universal Analytics
- New Relic
- Omniture SiteCatalyst
- Quantcast Measurement
- Twitter Analytics
- Twitter Conversion Tracking
- Twitter Website Universal Tag
cdn
10 products used
- AJAX Libraries API
- Akamai
- Amazon S3
- Azure Edge
- Cloudinary
- Content Delivery Network
- Microsoft Azure Blob Storage
- Microsoft Azure CDN
- Twitter CDN
- Yahoo Image CDN
cdns
1 product used
- Amazon CloudFront
GSK Company Culture![CultureAndCompensation Logo]()
Overall Culture
C+
74/100
CEO Rating
C
70/100
Compensation
C+
73/100
GSK News and Updates
Jun 14, 2021
iTeos stock jumps 60% after company announces deal with GSK
Shares of iTeos Therapeutics Inc. soared 58.5% in premarket trading on Monday after the company announced a deal with GlaxoSmithKline to develop and commercialize an experimental cancer therapy. GSK will make a $625 million upfront payment to iTeos, with an additional $1.4 billion in possible milestone payments available in the future. The immuno-oncology drug candidate is currently being tested in an open-label, Phase 1 clinical trial in patients with advanced solid tumors; as part of this deal, the companies plan to pair the iTeos drug with GSK's Jemperli in studies next year. (Jemperli was initially approved by the Food and Drug Administration as a treatment for endometrial cancer in April.) Shares of iTeos are down 40.8% so far this year, while the S&P 500 has gained 13.1%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Jun 14, 2021
iTeos Therapeutics and GSK announce development and commercialisation collaboration for EOS-448, an anti-TIGIT monoclonal antibody, enabling novel next-generation immuno-oncology combinationsJun 09, 2021
Progentic, GSK to partner in lupus researchProgentic, a provider of diagnostic and digital technologies for proactive management of autoimmune diseases, has announced an 18-month collaborative research agreement with GlaxoSmithKline to evaluate novel measurement and management tools for systemic lupus erythematosus.
Jun 08, 2021
Progentec Announces Research Collaboration with GSK to Assess Proteomics and Digital Health Tools for Lupus (SLE) CareProgentec, a leader in diagnostic and digital technologies for the proactive management of autoimmune diseases, announced today an 18-month collaborative research agreement with GlaxoSmithKline (GSK) to evaluate novel measurement and management tools for systemic lupus erythematosus ("SLE" or "lupus").
May 30, 2021
: The FDA authorized the third antibody infusion therapy. Here’s why Vir and GSK say the U.S. still needs COVID-19 treatments
There are now three antibody-based treatments available in the U.S. to treat adults and teens with mild or moderate forms of COVID-19, though all require intravenous infusions and are not the kind of medications that can be picked up at a local pharmacy.
May 29, 2021
Sanofi, GSK initiate Phase 3 clinical coronavirus vaccine trialFrench and British pharmaceutical companies announced on Friday that they will initiate global phase 3 clinical efficacy studies of a coronavirus vaccine candidate, Anadolu Agency reports.
GSK Blogs
Jun 12, 2020
ViiV Healthcare announces US FDA approval of the first-ever dispersible tablet formulation of dolutegravir, Tivicay PD, a once-daily treatment for children living with HIVPress release
Jun 04, 2020
GSK announces new data presentations from the DREAMM programme exploring investigational belantamab mafodotin in patients with relapsed/refractory multiple myeloma16 presentations, including new analyses from the pivotal DREAMM-2 study and initial results from the DREAMM-4 study
May 28, 2020
GSK announces intention to produce 1 billion doses of pandemic vaccine adjuvant in 2021 to support multiple COVID-19 vaccine collaborationsAnnouncement follows completion of global manufacturing review and decision to invest in expanded manufacturing capacity
May 27, 2020
DREAMM-2 and DREAMM-6 data at ASCO reinforce the potential of GSK’s investigational belantamab mafodotin in patients with relapsed/refractory multiple myelomaDREAMM-2 and DREAMM-6 data at ASCO reinforce the potential of GSK’s investigational belantamab mafodotin
May 27, 2020
FDA grants priority review of Nucala for patients with Hypereosinophilic Syndrome (HES)An approval would give Nucala a third indication in an eosinophil-driven disease
May 21, 2020
GSK partners with Samsung Biologics to secure additional manufacturing capacity for innovative biopharmaceutical portfolioGSK and Samsung Biologics have entered a partnership
You may also be interested in Related companies
Ozon Pharm
HQ
Zhigulevsk, RU
Employees
172
Ozon Pharm is a pharmaceutical company that manufactures medicines.
View company
Alfasigma
HQ
Bologna, IT
Employees
1563
Alfasigma is a pharmaceutical company providing prescription and over-the-counter drugs.
View company
Corbus Pharmaceuticals
HQ
Norwood, US
Employees
141 ↑ 83% increase
Corbus Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company.
View company- When was GSK founded?
- GSK was founded in 2000.
- Who are GSK key executives?
- GSK's key executives are Faris El Refaie, Sridhar Venkatesh and Iain MacKay.
- How many employees does GSK have?
- GSK has 99,437 employees.
- What is GSK revenue?
- Latest GSK annual revenue is £33.75 b.
- What is GSK revenue per employee?
- Latest GSK revenue per employee is £339.45 k.
- Who are GSK competitors?
- Competitors of GSK include Johnson & Johnson, Roche and AstraZeneca.
- Where is GSK headquarters?
- GSK headquarters is located at 980 Great West Rd, Brentford.
- Where are GSK offices?
- GSK has offices in Brentford, Philadelphia, Boudouaou, San Fernando and 86 other locations
- How many offices does GSK have?
- GSK has 90 offices.
Craft real-time company insights
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies